Search
Takeda Pharmaceutical Co Ltd
TAKAdd to Watchlist
15.845USD
+0.375+2.42%
Market hours （ET）Quotes delayed by 15 min
50.07BMarket Cap
41.31P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.42%
5 Days
+0.48%
1 Month
-2.49%
6 Months
+4.93%
Year to Date
+1.64%
1 Year
+7.28%
Key Figures
15.520Open
15.850High
1.30MVolume
41.31P/E TTM
10.35P/E Dynamic
0.994Dividend TTM
0.04%Turnover Ratio
15.470Prev. Close
15.500Low
9.86MTurnover
0.46P/E Static
1.06P/B
6.27%Div Yield TTM
1.29%ROA
18.89552wk High
0.83Volume Ratio
107.93BNet Profit
3.16BShares
0.3836EPS TTM
-0.04Beta
2.61%ROE
12.99052wk Low
2.26%Amplitude
48.79%Gross Margin
50.07BMarket Cap
-7.61Reward/Risk
0.81%Risk Rate
TradingKey Stock Score of Takeda Pharmaceutical Co Ltd
Currency: USD Updated: 2026-06-22Key Insights
Takeda Pharmaceutical Co Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.80.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Takeda Pharmaceutical Co Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Takeda Pharmaceutical Co Ltd Highlights
StrengthsRisks
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 287.84%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 287.84%.
Fairly Valued
The company’s latest PE is 40.33, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 85.31M shares, decreasing 8.71% quarter-over-quarter.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
20.800
Target Price
+33.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Takeda Pharmaceutical Co Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Takeda Pharmaceutical Co Ltd Info
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Ticker SymbolTAK
CompanyTakeda Pharmaceutical Co Ltd
CEOWeber (Christophe)
Websitehttps://www.takeda.com/
Related Instruments
+0.21%
+2.43%
+2.20%
+2.07%
+2.94%
+2.72%
+0.90%
+2.06%
+0.86%
-0.44%
+0.77%
+1.73%
+2.24%
-0.25%
+2.74%
0.00%
+1.00%
+3.18%
+1.97%Popular Instruments
73.175
-0.814 (-1.10%)
299.060
+2.050 (+0.69%)
202.140
-6.510 (-3.12%)
4130.860
-59.390 (-1.42%)
674.830
-57.790 (-7.89%)
1980.320
-293.410 (-12.90%)
1076.830
-134.550 (-11.11%)
347.600
-2.080 (-0.59%)
62612.430
-1791.370 (-2.78%)
384.650
-20.400 (-5.04%)
FAQs
What is the current price of Takeda Pharmaceutical Co Ltd (TAK)?
The current price of Takeda Pharmaceutical Co Ltd (TAK) is 15.46.
What is the symbol of Takeda Pharmaceutical Co Ltd?
The ticker symbol of Takeda Pharmaceutical Co Ltd is TAK.
What is the 52-week high of Takeda Pharmaceutical Co Ltd?
The 52-week high of Takeda Pharmaceutical Co Ltd is 18.89.
What is the 52-week low of Takeda Pharmaceutical Co Ltd?
The 52-week low of Takeda Pharmaceutical Co Ltd is 12.99.
What is the market capitalization of Takeda Pharmaceutical Co Ltd?
The market capitalization of Takeda Pharmaceutical Co Ltd is 49.01B.
Is Takeda Pharmaceutical Co Ltd (TAK) currently rated as Buy, Hold, or Sell?
According to analysts, Takeda Pharmaceutical Co Ltd (TAK) has an overall rating of Buy, with a price target of 20.80.
What is the Earnings Per Share (EPS TTM) of Takeda Pharmaceutical Co Ltd (TAK)?
The Earnings Per Share (EPS TTM) of Takeda Pharmaceutical Co Ltd (TAK) is -0.30.
